Price Alert

Avadel Pharmaceuticals (AVDL)

NASDAQ: AVDL · Real-Time Price · USD

15.01

0.07 (0.47%)

At close: Oct 03, 2025, 3:59 PM

15.03

0.13%

After-hours: Oct 03, 2025, 05:10 PM EDT

Avadel Pharmaceuticals Statistics

Share Statistics

Avadel Pharmaceuticals has 96.5M shares outstanding. The number of shares has increased by 0.14% in one year.

Shares Outstanding	96.5M
Shares Change (YoY)	0.14%
Shares Change (QoQ)	-0.41%
Owned by Institutions (%)	83.44%
Shares Floating	80.64M
Failed to Deliver (FTD) Shares	20
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 10.44M, so 10.76% of the outstanding shares have been sold short.

Short Interest	10.44M
Short % of Shares Out	10.76%
Short % of Float	12.56%
Short Ratio (days to cover)	6.09

Valuation Ratios

The PE ratio is -20.48 and the forward PE ratio is 17.37. Avadel Pharmaceuticals's PEG ratio is 0.27.

PE Ratio	-20.48
Forward PE	17.37
PS Ratio	5.91
Forward PS	4.1
PB Ratio	13.54
P/FCF Ratio	-21.32
PEG Ratio	0.27

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Avadel Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.02.

Current Ratio	2.75
Quick Ratio	2.33
Debt / Equity	0.02
Debt / EBITDA	-0.05
Debt / FCF	-0.04
Interest Coverage	-3.91

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$899.56K
Profits Per Employee	$-259.74K
Employee Count	188
Asset Turnover	1.03
Inventory Turnover	0.75

Taxes

Income Tax	-247K
Effective Tax Rate	0.5%

Stock Price Statistics

The stock price has increased by 14.67% in the last 52 weeks. The beta is 1.46, so Avadel Pharmaceuticals's price volatility has been higher than the market average.

Beta	1.46
52-Week Price Change	14.67%
50-Day Moving Average	14.14
200-Day Moving Average	10.2
Relative Strength Index (RSI)	49.57
Average Volume (20 Days)	1,293,906

Income Statement

In the last 12 months, Avadel Pharmaceuticals had revenue of 169.12M and earned -48.83M in profits. Earnings per share was -0.51.

Revenue	169.12M
Gross Profit	153.84M
Operating Income	-42.4M
Net Income	-48.83M
EBITDA	-35.57M
EBIT	-38.25M
Earnings Per Share (EPS)	-0.51

Full Income Statement

Balance Sheet

The company has 51.37M in cash and 1.7M in debt, giving a net cash position of 49.67M.

Cash & Cash Equivalents	51.37M
Total Debt	1.7M
Net Cash	49.67M
Retained Earnings	-794.33M
Total Assets	187.16M
Working Capital	102.04M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -46.91M and capital expenditures 0, giving a free cash flow of -46.91M.

Operating Cash Flow	-46.91M
Capital Expenditures	n/a
Free Cash Flow	-46.91M
FCF Per Share	-0.49

Full Cash Flow Statement

Margins

Gross margin is 90.97%, with operating and profit margins of -25.07% and -28.87%.

Gross Margin	90.97%
Operating Margin	-25.07%
Pretax Margin	-29.02%
Profit Margin	-28.87%
EBITDA Margin	-21.03%
EBIT Margin	-25.07%
FCF Margin	-27.74%

Dividends & Yields

AVDL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for AVDL is $19, which is 26.6% higher than the current price. The consensus rating is "Buy".

Price Target	$19
Price Target Difference	26.6%
Analyst Consensus	Buy
Analyst Count	7

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	5.19
Piotroski F-Score	4